Anupam Rasayan to Acquire 43.3-48.2% Stake in Bliss GVS Pharma
Anupam Rasayan India Limited will acquire a 43.3-48.2% stake in Bliss GVS Pharma Limited for ₹300 Crores via term loan and equity instruments. This move aims to strengthen Anupam Rasayan's pharmaceutical value chain presence and global reach.
The acquisition is a significant corporate action that will substantially alter the company's business scope and market presence, indicating a high impact.
The acquisition of a significant stake in Bliss GVS Pharma Limited is a strategic move that is expected to strengthen Anupam Rasayan's presence in the pharmaceutical value chain and expand its global reach, which is positive for the company.
Anupam Rasayan India Limited has announced its definitive agreement to acquire a 43.3-48.2% equity stake in Bliss GVS Pharma Limited, a pharmaceutical formulations company. This acquisition also includes an open offer to the public shareholders of Bliss GVS Pharma.
The total purchase consideration for this acquisition has been financed through ₹300 Crores via a Term Loan and a non-controlling non-voting equity instrument for the balance amount.
Bliss GVS Pharma Limited is an India-based pharmaceutical formulations company involved in the development, manufacturing, marketing, and export of various dosage forms. It has a strong presence in regulated and semi-regulated international markets, particularly in Africa, Asia, and Latin America. The company is noted for its leadership in suppositories and pessaries and holds EU-GMP certification. Its product portfolio includes over 150 branded formulations across therapeutic areas like antimalarial, antifungal, antibacterial, anti-inflammatory, and women's healthcare. Bliss GVS Pharma operates multiple manufacturing facilities in Maharashtra and Daman, approved by US FDA, WHO-GMP, and EU-GMP.
Mr. Anand Desai, Managing Director of Anupam Rasayan India Ltd., stated that this acquisition marks a significant milestone in building an integrated global life sciences and specialty pharmaceutical platform. He believes it will strategically strengthen their presence across the pharmaceutical value chain, from KSMs to finished dosage formulations. The combined entity aims to create a broader, integrated, and diversified pharmaceutical manufacturing ecosystem with deeper backward integration and enhanced global reach, especially in Europe and America.
Anupam Rasayan India Ltd. is a leading custom synthesis and specialty chemicals manufacturer, serving over 185 domestic and international customers through eight manufacturing facilities.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.